Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H16F3NO.ClH |
Molecular Weight | 331.76 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NCC[C@H](OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2
InChI
InChIKey=GMTWWEPBGGXBTO-RSAXXLAASA-N
InChI=1S/C16H16F3NO.ClH/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12;/h1-9,15H,10-11,20H2;1H/t15-;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1279447Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15886723 | https://www.ncbi.nlm.nih.gov/pubmed/10208643 | https://www.ncbi.nlm.nih.gov/pubmed/8512621
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1279447
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15886723 | https://www.ncbi.nlm.nih.gov/pubmed/10208643 | https://www.ncbi.nlm.nih.gov/pubmed/8512621
Seproxetine, also known as (S)-norfluoxetine, is a selective serotonin reuptake inhibitor (SSRI). It is the most important active metabolite of the widely used antidepressant fluoxetine, but little is known about its pharmacological actions. Seproxetine was being investigated by Eli Lilly and Company as an antidepressant; however, a cardiac side effect was noted and development was discontinued.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19014888 |
4544.0 nM [Ki] | ||
Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19014888 |
6186.0 nM [Ki] | ||
Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19014888 |
50.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8512621
Rats were treated with Norfluoxetine (0-20mg/kg)
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8512621
Rat cortical membranes equivalent to 50 mkg of protein were incubated at 37°C for 30 minutes in 2 ml of reaction medium containing the (S)-Norfluoxetine (1-1000nM), 0.1 nM [3Hlparoxetine, 50 mmol/L Tris-HG, pH 7.4, 150 mmol/L NaG, and 5 mmol/L KCl. Fluoxetine at 1 mkM/kg was used to determine nonspecific binding
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Fri Dec 15 16:05:06 GMT 2023 , Edited by admin on Fri Dec 15 16:05:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT000562
Created by
admin on Fri Dec 15 16:05:06 GMT 2023 , Edited by admin on Fri Dec 15 16:05:06 GMT 2023
|
PRIMARY | |||
|
DTXSID00155625
Created by
admin on Fri Dec 15 16:05:06 GMT 2023 , Edited by admin on Fri Dec 15 16:05:06 GMT 2023
|
PRIMARY | |||
|
CHEMBL465123
Created by
admin on Fri Dec 15 16:05:06 GMT 2023 , Edited by admin on Fri Dec 15 16:05:06 GMT 2023
|
PRIMARY | |||
|
C73809
Created by
admin on Fri Dec 15 16:05:06 GMT 2023 , Edited by admin on Fri Dec 15 16:05:06 GMT 2023
|
PRIMARY | |||
|
127685-30-7
Created by
admin on Fri Dec 15 16:05:06 GMT 2023 , Edited by admin on Fri Dec 15 16:05:06 GMT 2023
|
PRIMARY | |||
|
K4QYN23H2N
Created by
admin on Fri Dec 15 16:05:06 GMT 2023 , Edited by admin on Fri Dec 15 16:05:06 GMT 2023
|
PRIMARY | |||
|
3058750
Created by
admin on Fri Dec 15 16:05:06 GMT 2023 , Edited by admin on Fri Dec 15 16:05:06 GMT 2023
|
PRIMARY | |||
|
CC-46
Created by
admin on Fri Dec 15 16:05:06 GMT 2023 , Edited by admin on Fri Dec 15 16:05:06 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD